Class-leading proliferation of primary human endothelial cells over extended periods, all in a serum-free, clinically ready formulation.
Catalog |
CnT-PR-EN-HC |
Content |
500 ml medium w/o serum |
|
|
HIGHLIGHTS:
- Longevity of cells
- Extended QC, documentation, support, and process control for clinical researchers
- Serum-free formulation enables the end user to supplement with serum validated to deliver the desired cell behavior and known to meet the necessary regulatory requirements
Description
CnT-PR-EN-HC medium is a highly refined medium for high efficiency isolation and expansion of primary human endothelial cells. The basal medium is also supplemented with a range of Progenitor Cell Targeted (PCT) growth factors to extend longevity and co-factors to improve growth factor binding to membrane-bound receptors. It does not contain phenol-red or antibiotics/antimycotics. CnT-PR-EN-HC medium is ideally suited for use during product development, protocol validation, and characterization of the cell-based product. HANDLING INSTRUCTION: For optimized performance of CnT-PR-EN-HC medium, we recommend sourcing and supplementing 1 % serum suiting your clinical application.
Back to top
Specifications
- Tissue type
- Endothelial cells
- Application
- Isolation / Expansion
- Serum
- Supplementation by User
- BPE
- No
- Free of Human & Animal Component
- Yes
- Chemically defined
- Yes
- Clinically upgradable
- Yes
- Volume
- 500 ml
- Component(s)
- Frozen Bottle & Ready-to-use
- Quality level
- Higher Certified
Back to top
Scientific resources
Figure: Primary HUVEC cells growing in CnT-PR-EN-HC medium at Passage 5 and Passage 9.
Primary human endothelial cells growing in CnT-PR-EN-HC retain enhanced proliferation and extended growth. It uses an advanced basal medium supplemented with a range of growth factors and is FBS-free. We recommend use of 1 % serum for optimal performance.
Cells demonstrate the correct localization of VE-Cadherin, a critical regulator of endothelial cell behaviour.
Functionality of the HUVEC cells is also evident in the successful completion of a tube formation assay.
Figure: Primary HUVEC cells demonstrate correct juntional localization of VE-Cadherin under both static and flow (1.4 Pa) conditions. Analysis courtesy of Georgios Stefanopoulos, Laboratory of Thermodynamics in Emerging Technologies, ETH Zurich.
Figure: Tube formation (microvascular-on-a-chip) and in vitro modeling of blood clotting by primary HUVEC cells grown in CnT-PR-EN-HC medium (upper). Red: live cell staining. Green: Fluorochrom-labelled fibrinogen. Control: cells in EGM-2 medium (lower). Image courtesy of the Schroeder Group, Experimental Haemostasis, University of Bern.
Click to enlarge image. HUVEC growing in CnT-PR-EN-HC medium offer increased proliferate rates and longevity in comparison with EGM-2 medium. Image courtesy of the Schroeder Group, Experimental Haemostasis, University of Bern.
For an overview of the performance of HUVEC growing in CnT-PR-EN-HC medium, please download this A4 Flyer.
Back to top
Scientific Literature
Title |
Authors |
Year |
Tissue type |
A microfluidic platform integrating functional vascularized organoids-on-chip |
Clément Quintard, Gustav Jonsson, Camille Laporte, Caroline Bissardon, Amandine Pitaval, Nicolas Werschler, Alexandra Leopoldi, Astrid Hagelkrüys, Pierre Blandin, Jean-Luc Achard, Fabrice Navarro,Yves Fouillet, Josef M. Penninger, Xavier Gidrol |
2024 |
Other |
Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model |
Murielle Golomingi, Jessie Kohler, Lorenz Jenny, Elaissa T. Hardy, Jozsef Dobo, Peter Ga, Gabor Pa, Bence Kiss, Wilbur A. Lam and Verena Schroeder |
2022 |
Other |
Real-time monitoring of oxygen levels within thermoplastic Organ-on-Chip devices |
Anubhav Bussooa, Emily Tubbs, Frederic Revol-Cavalier, Ayman Chmayssem, Manuel Alessio, Marie-Line Cosnier, Nicolas Verplanck |
2022 |
Other |
Title |
Year |
CELLnTEC Catalog |
2023 |
Download |
Back to top